- Home
- IONS vs LCID Comparison
IONS vs LCID Comparison
Compare IONS & LCID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- LCID
- Stock Information
- Founded
- IONS 1989
- LCID 2007
- Country
- IONS United States
- LCID United States
- Employees
- IONS N/A
- LCID N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- LCID Auto Manufacturing
- Sector
- IONS Health Care
- LCID Consumer Discretionary
- Exchange
- IONS Nasdaq
- LCID Nasdaq
- Market Cap
- IONS 6.8B
- LCID 6.9B
- IPO Year
- IONS 1991
- LCID N/A
- Fundamental
- Price
- IONS $42.25
- LCID $2.92
- Analyst Decision
- IONS Buy
- LCID Hold
- Analyst Count
- IONS 15
- LCID 9
- Target Price
- IONS $57.13
- LCID $3.00
- AVG Volume (30 Days)
- IONS 1.8M
- LCID 193.0M
- Earning Date
- IONS 07-30-2025
- LCID 08-05-2025
- Dividend Yield
- IONS N/A
- LCID N/A
- EPS Growth
- IONS N/A
- LCID N/A
- EPS
- IONS N/A
- LCID N/A
- Revenue
- IONS $717,253,000.00
- LCID $870,140,000.00
- Revenue This Year
- IONS $9.08
- LCID $75.04
- Revenue Next Year
- IONS $14.72
- LCID $97.81
- P/E Ratio
- IONS N/A
- LCID N/A
- Revenue Growth
- IONS N/A
- LCID 40.67
- 52 Week Low
- IONS $23.95
- LCID $1.93
- 52 Week High
- IONS $52.34
- LCID $4.43
- Technical
- Relative Strength Index (RSI)
- IONS 60.76
- LCID 61.76
- Support Level
- IONS $41.25
- LCID $2.75
- Resistance Level
- IONS $42.81
- LCID $3.31
- Average True Range (ATR)
- IONS 1.18
- LCID 0.22
- MACD
- IONS -0.27
- LCID 0.07
- Stochastic Oscillator
- IONS 42.36
- LCID 64.29
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
About LCID Lucid Group Inc.
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It offers its own geographically distributed retail and service locations and through direct-to-consumer online and retail sales. It also boasts a product roadmap of future vehicle programs and technologies. It focuses on in-house hardware and software innovation, vertical integration, and a clean-sheet approach to engineering and design led to the development of the Lucid Air. The Lucid Air is a luxury sedan that redefines both the luxury car segment and the EV space. Its geographic segments include North America, the Middle East, and Other International.